Peter M. Neupert
Peter M. Neupert's purchase track record
How the stock did after each of Peter M. Neupert's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/8/2025 | FTRE | $407K | +71.0% | +122.6% | +8.5% |
| 8/23/2023 | FTRE | $278K | +29.5% | +43.4% | +12.3% |
| 2/16/2022 | LH | $923K | -9.8% | -5.5% | -4.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Barclays Upgrades Fortrea, Boosts Target to $23. Barclays has upgraded Fortrea Holdings to overweight and lifted its target price to $23. The upgrade follows a recent rise in the stock price and a mention of the company as an overrated pick in a Yahoo article. Analysts still see upside potential, with the average target of $21.04 and a 52‑week range that includes the new level. The stock’s high‑beta rating indicates it may continue to move sharply with market swings.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Labcorp to Acquire OPKO Health's BioReference Assets for $722M. Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.
Transaction History
| ADPT | ▲ Buy | Option Exercise | 15,000 | $95K | 8/17/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 15,000 | $378K | 8/17/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 40,000 | $1.0M | 8/17/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 69,690 | $1.8M | 8/17/2026 | View on chart |
| FTRE | ▲ Buy | Option Exercise | 148,536 | $0 | 5/14/2026 | View on chart |
| ADPT | ▲ Buy | Grant | 15,625 | $0 | 3/4/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 897 | — | 2/11/2026 | View on chart |
| FTRE | ▲ Buy | Open Market | 32,500 | $203K | 8/11/2025 | View on chart |
| FTRE | ▲ Buy | Open Market | 30,000 | $204K | 8/8/2025 | View on chart |
| FTRE | ▲ Buy | Option Exercise | 7,282 | $0 | 5/14/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 50,000 | $204K | 3/10/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 10,000 | $71K | 3/10/2025 | View on chart |
| ADPT | ▲ Buy | Grant | 15,394 | $0 | 3/4/2025 | View on chart |
| LH | ▲ Buy | Option Exercise | 944 | — | 2/6/2025 | View on chart |
| FTRE | ▲ Buy | Option Exercise | 6,354 | $0 | 7/18/2024 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 15,000 | $13K | 3/12/2024 | View on chart |
| ADPT | ▲ Buy | Grant | 31,328 | $0 | 3/4/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 947 | — | 2/7/2024 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 100,000 | $84K | 12/13/2023 | View on chart |
| FTRE | ▲ Buy | Open Market | 11,000 | $278K | 8/23/2023 | View on chart |
| ADPT | ▲ Buy | Grant | 14,775 | $0 | 3/6/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 742 | — | 2/11/2023 | View on chart |
| LH | ▲ Buy | Open Market | 1,300 | $342K | 2/16/2022 | View on chart |
| LH | ▲ Buy | Open Market | 1,600 | $422K | 2/16/2022 | View on chart |
| LH | ▲ Buy | Open Market | 600 | $159K | 2/16/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 771 | — | 2/2/2022 | View on chart |
| ADPT | ▲ Buy | Grant | 6,689 | $0 | 1/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism
Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.